Navigation Links
Tengion to Host Conference Call to Provide a Business Update and Report First Quarter 2011 Financial Results on May 12, 2011
Date:5/4/2011

EAST NORRITON, Pa., May 4, 2011 /PRNewswire/ -- Tengion, Inc. (Nasdaq: TNGN), a leader in regenerative medicine, today announced it will host a conference call and live audio webcast on Thursday, May 12, 2011 at 8:30 a.m. EDT to provide a business update and discuss its first quarter 2011 financial results.  

To participate in the call, please dial 1-866-383-7989 (domestic) or 1-617-597-5328 (international) and reference access code 64874944.

This conference call will also be webcast live and can be accessed from the Investors section of the Company's website at http://www.tengion.com or at http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=218965&eventID=4014467.  The webcast will be archived on the website until June 12, 2011.  

About Tengion

Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform™ that enables the Company to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Tengion's product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. An initial clinical trial is ongoing for the Company's lead product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company's lead preclinical program is the Neo-Kidney Augment™, which is designed to delay or prevent the need for dialysis or transplantation in patients at risk for kidney failure. Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment™ for the treatment of neurogenic bladder. Tengion has worldwide rights to its product candidates. For more information, please visit www.tengion.com.


'/>"/>
SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel
2. Tengion To Host Conference Call To Provide a Business Update and Report Fourth Quarter 2010 Financial Results on March 25, 2011
3. Tengion Announces Pricing of $31.4 Million Private Placement
4. Tengion Addresses Recent Trading Activity in its Common Stock
5. Tengion to Present at the 13th Annual BIO CEO & Investor Conference and the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
6. Tengion Presents New Large Animal Data Demonstrating Functional Kidney Regeneration at the American Society for Transplantation Annual Conference
7. Tengion Appoints Richard E. Kuntz, MD to its Board of Directors
8. Tengion Announces Webcast of Analyst and Investor Meeting on October 27, 2010
9. Tengion Appoints A. Brian Davis Chief Financial Officer
10. Tengion Presents New Data Supporting its Organ Regeneration Platform™ at 8th Annual Meeting of the International Society for Stem Cell Research
11. Tengion Presents New Data Supporting Key Urologic and Kidney Programs at 16th Annual Meeting of the International Society for Cellular Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... 19, 2017 , ... November Research Group, LLC, a global ... device manufacturers and regulators, is proud to announce the worldwide release of PRIMO ... to provide product vigilance departments with the flexibility and ease of use of ...
(Date:1/19/2017)... ... January 18, 2017 , ... The American Medical ... update its Data Sharing Policy. Specifically, the nation’s leading informatics experts, said data ... the existing policy. AMIA recommended that NIH earmark funding for researchers to produce ...
(Date:1/19/2017)... The global biotechnology services outsourcing market ... 2025, according to a new report by Grand ... of the function of outsourcing certain clinical and ... services outsourced, clinical trial management and contract manufacturing ... was the first pharmaceutical company to outsource its ...
(Date:1/18/2017)... ... 2017 , ... Opal Kelly, a leading producer of powerful ... the ZEM5310 USB 3.0 FPGA Module, combining a SuperSpeed USB 3.0 interface and ... suitable for prototyping, testing, and production-ready integration. The ZEM5310 USB interface delivers real-world ...
Breaking Biology Technology:
(Date:12/15/2016)... Germany , December 15, 2016 ... announced an agreement with NuData Security, an award-winning ... partnership will enable clients to focus on good customer experience, ... protection regulation. ... In order to provide a one-stop fraud prevention suite, ...
(Date:12/15/2016)... -- "Increase in mobile transactions is driving the growth ... is expected to grow from USD 4.03 billion in ... CAGR of 29.3% between 2016 and 2022. The market ... for smart devices, government initiatives, and increasing penetration of ... expected to grow at a high rate during the ...
(Date:12/7/2016)... Israel , December 7, 2016 BioCatch ... the expansion of its patent portfolio, which grew to over 40 granted ... , , ... its recently filed patent entitled " System, Device, and Method ... technology that enables device makers to forego costly hardware components needed to ...
Breaking Biology News(10 mins):